These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 27599663)

  • 61. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis.
    Schmitt C; Kuhn B; Zhang X; Kivitz AJ; Grange S
    Clin Pharmacol Ther; 2011 May; 89(5):735-40. PubMed ID: 21430660
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations.
    Bihorel S; Fiedler-Kelly J; Ludwig E; Sloan-Lancaster J; Raddad E
    AAPS J; 2014 Sep; 16(5):1009-17. PubMed ID: 24912797
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
    Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
    Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series.
    Talotta R; Atzeni F; Batticciotto A; Ditto MC; Gerardi MC; Sarzi-Puttini P
    J Med Case Rep; 2018 Jun; 12(1):154. PubMed ID: 29859543
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.
    Gandhi Y; Passarell JA; Roy A; Murthy B
    J Clin Pharmacol; 2021 May; 61(5):688-699. PubMed ID: 33284480
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
    Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
    J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study.
    Balsa A; Tovar Beltrán JV; Cáliz Cáliz R; Mateo Bernardo I; García-Vicuña R; Rodríguez-Gómez M; Belmonte Serrano MA; Marras C; Loza Cortina E; Pérez-Pampin E; Vila V
    Rheumatol Int; 2015 Sep; 35(9):1525-34. PubMed ID: 25773655
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes.
    Arrivé C; Bazzoli C; Jouve T; Noble J; Rostaing L; Stanke-Labesque F; Djerada Z
    BioDrugs; 2024 Sep; 38(5):703-716. PubMed ID: 39147956
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
    Burmester GR; Choy E; Kivitz A; Ogata A; Bao M; Nomura A; Lacey S; Pei J; Reiss W; Pethoe-Schramm A; Mallalieu NL; Wallace T; Michalska M; Birnboeck H; Stubenrauch K; Genovese MC
    Ann Rheum Dis; 2017 Jun; 76(6):1078-1085. PubMed ID: 28007755
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Local versus systemic anti-tumour necrosis factor-α effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug.
    Stepensky D
    Clin Pharmacokinet; 2012 Jul; 51(7):443-55. PubMed ID: 22540283
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evaluation of etanercept dose reduction in patients with rheumatoid arthritis using pharmacokinetic/pharmacodynamic modeling and simulation.
    Hsu LF; Huang JD
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):776-86. PubMed ID: 24887337
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.
    Bykerk VP; Östör AJ; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Aassi M; Sibilia J
    Clin Rheumatol; 2015 Mar; 34(3):563-71. PubMed ID: 25604316
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.
    Genovese MC; Kremer JM; van Vollenhoven RF; Alten R; Scali JJ; Kelman A; Dimonaco S; Brockwell L
    Arthritis Rheumatol; 2017 Sep; 69(9):1751-1761. PubMed ID: 28597609
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Doubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious.
    Lindegaard HM; Johansen P; Gröndal G; Jensen EC; Juul L; Schlemmer AM; Agular B; Hansen I
    Scand J Rheumatol; 2016 Jul; 45(4):262-6. PubMed ID: 26727655
    [TBL] [Abstract][Full Text] [Related]  

  • 77. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.
    Genovese MC; Van den Bosch F; Roberson SA; Bojin S; Biagini IM; Ryan P; Sloan-Lancaster J
    Arthritis Rheum; 2010 Apr; 62(4):929-39. PubMed ID: 20131262
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.
    Takeuchi T; Thorne C; Karpouzas G; Sheng S; Xu W; Rao R; Fei K; Hsu B; Tak PP
    Ann Rheum Dis; 2017 Dec; 76(12):2001-2008. PubMed ID: 28855173
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
    Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T;
    Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782
    [TBL] [Abstract][Full Text] [Related]  

  • 80. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy.
    Rao VU; Pavlov A; Klearman M; Musselman D; Giles JT; Bathon JM; Sattar N; Lee JS
    Arthritis Rheumatol; 2015 Feb; 67(2):372-80. PubMed ID: 25332171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.